Alessandro Previtali

1.4k total citations · 1 hit paper
18 papers, 374 citations indexed

About

Alessandro Previtali is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Alessandro Previtali has authored 18 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 6 papers in Immunology. Recurrent topics in Alessandro Previtali's work include CAR-T cell therapy research (10 papers), Lymphoma Diagnosis and Treatment (6 papers) and Biosimilars and Bioanalytical Methods (4 papers). Alessandro Previtali is often cited by papers focused on CAR-T cell therapy research (10 papers), Lymphoma Diagnosis and Treatment (6 papers) and Biosimilars and Bioanalytical Methods (4 papers). Alessandro Previtali collaborates with scholars based in United States, Switzerland and Germany. Alessandro Previtali's co-authors include Sami Ibrahimi, Matthew A. Lunning, Alessandro Crotta, Jeremy S. Abramson, Jon Arnason, Pim Mutsaers, Manali Kamdar, Patrick B. Johnston, Sandrine Montheard and Koji Izutsu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Alessandro Previtali

14 papers receiving 370 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

2022 186 citations Jeremy S. Abramson, Scott R. Solomon et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alessandro Previtali United States	7	257	111	101	84	76	18	374
Alessandro Crotta United States	7	273 1.1×	121 1.1×	99 1.0×	48 0.6×	55 0.7×	26	369
Houston Holmes United States	12	319 1.2×	146 1.3×	202 2.0×	88 1.0×	119 1.6×	39	540
Christine Dehner United States	11	402 1.6×	152 1.4×	153 1.5×	88 1.0×	112 1.5×	19	520
Sami Ibrahimi United States	9	277 1.1×	158 1.4×	47 0.5×	49 0.6×	61 0.8×	33	387
Lori A. Leslie United States	11	252 1.0×	168 1.5×	48 0.5×	61 0.7×	84 1.1×	73	412
Elizabeth Budde United States	9	161 0.6×	63 0.6×	88 0.9×	105 1.3×	48 0.6×	26	275
Noemi Mergen Germany	8	503 2.0×	186 1.7×	195 1.9×	57 0.7×	135 1.8×	13	687
David Sermer United States	10	219 0.9×	106 1.0×	30 0.3×	112 1.3×	93 1.2×	22	387
Pim Mutsaers Netherlands	8	270 1.1×	185 1.7×	28 0.3×	51 0.6×	59 0.8×	30	371
Hien Liu United States	11	449 1.7×	153 1.4×	144 1.4×	156 1.9×	67 0.9×	62	594

Countries citing papers authored by Alessandro Previtali

Since Specialization

Citations

This map shows the geographic impact of Alessandro Previtali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandro Previtali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandro Previtali more than expected).

Fields of papers citing papers by Alessandro Previtali

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alessandro Previtali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandro Previtali. The network helps show where Alessandro Previtali may publish in the future.

Co-authorship network of co-authors of Alessandro Previtali

This figure shows the co-authorship network connecting the top 25 collaborators of Alessandro Previtali. A scholar is included among the top collaborators of Alessandro Previtali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandro Previtali. Alessandro Previtali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2024). Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen. Future Oncology. 20(21). 1455–1465. 1 indexed citations

Abramson, Jeremy S., Manali Kamdar, Alessandro Crotta, et al.. (2024). Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up. Blood. 144(Supplement 1). 3130–3130.

Nastoupil, Loretta J., Manali Kamdar, Julio C. Chávez, et al.. (2023). LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE. Hematological Oncology. 41(S2). 212–214.

Morschhauser, Franck, Hervé Ghesquières, Manali Kamdar, et al.. (2023). Comparison of overall survival of lisocabtagene maraleucel (liso‐cel) versus standard of care (SOC) adjusting for crossover in second‐line (2L) R/R large B‐cell lymphoma. Hematological Oncology. 41(S2). 451–452.

Nastoupil, Loretta J., Manali Kamdar, Julio C. Chávez, et al.. (2023). Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy.. Journal of Clinical Oncology. 41(16_suppl). 7526–7526. 2 indexed citations

Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2022). Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor T Cell Therapy, Compared with Standard of Care (SOC) Using Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study. Transplantation and Cellular Therapy. 28(3). S188–S189.

Abramson, Jeremy S., Patrick B. Johnston, Manali Kamdar, et al.. (2022). Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Advances. 6(23). 5969–5979. 17 indexed citations

Abramson, Jeremy S., Manali Kamdar, Fei‐Fei Liu, et al.. (2022). Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL). Blood. 140(Supplement 1). 4655–4656. 1 indexed citations

Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2022). Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study. Blood. 140(Supplement 1). 1581–1583. 6 indexed citations

10.

Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2022). Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 141(14). 1675–1684. 186 indexed citations breakdown →

11.

Zeidan, Amer M., Isaac W. Boss, C.L. Beach, et al.. (2021). A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Advances. 6(7). 2219–2229. 64 indexed citations

12.

Ananthakrishnan, Revathi, Stephanie Green, Alessandro Previtali, et al.. (2021). Critical review of oncology clinical trial design under non-proportional hazards. Critical Reviews in Oncology/Hematology. 162. 103350–103350. 17 indexed citations

13.

Abramson, Jeremy S., Scott R. Solomon, Jon Arnason, et al.. (2021). Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study. Blood. 138(Supplement 1). 3845–3845. 6 indexed citations

14.

Zeidan, Amer M., James D. Cavenagh, Maria Teresa Voso, et al.. (2019). Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study. Blood. 134(Supplement_1). 829–829. 60 indexed citations

15.

Vermeire, Séverine, Edward V. Loftus, Jean‐Frédéric Colombel, et al.. (2017). Long-Term Effectiveness and Safety of Vedolizumab in Patients with Crohn’s Disease: 5-Year Cumulative Exposure of Gemini 2 Completers Rolling Into the Gemini Open-Label Extension Study. Gastroenterology. 152(5). S601–S601. 9 indexed citations

16.

Vermeire, Séverine, Edward V. Loftus, J F Colombel, et al.. (2017). DOP021 Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study. Journal of Crohn s and Colitis. 11(suppl_1). S39–S39. 3 indexed citations

17.

Vermeire, Séverine, Brian G. Feagan, Reema Mody, Alessandro Previtali, & Brihad Abhyankar. (2016). Mo1879 Response and Remission Rates With Up to 3 Years of Vedolizumab Treatment in Patients With Crohn's Disease. Gastroenterology. 150(4). S803–S804. 1 indexed citations

18.

Loftus, Edward V., Jean‐Frédéric Colombel, Alessandro Previtali, & Michael Smyth. (2016). Mo1883 Response and Remission Rates With up to 3 Years of Vedolizumab Treatment in Patients with Ulcerative Colitis. Gastroenterology. 150(4). S805–S805. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact